Pablo Legorreta is the founder, CEO, and Chairman of Royalty Pharma plc. He has deployed over $20 billion for funding biopharmaceutical advancements and serves as a board member of ITB-MED. Pablo co-founded Pharmakon Advisors and ProKidney, LLC, and founded and chairs Alianza Médica para la Salud. He also serves on the boards of the New York Academy of Sciences and Rockefeller University. Prior to Royalty Pharma, he was an investment banker at Lazard Frères in Paris and New York. He has served on the board of the Zelarion Group since 2018.

Chairman of the Board

Pablo Legorreta

David Sachs is an immunologist renowned for his work in transplant immune tolerance and xenotransplantation. He graduated from Harvard College and Harvard Medical School and discovered MHC class II in 1973. He developed the first clinical protocol for organ transplantation tolerance induction in the early 2000s. He has served on the board of the Zelarion Group since 2016.

Director

David Sachs

Jan Ståhlberg is the CEO of Trill Impact and a board member of Bactiguard AB, ITB-MED, and Trelleborg AB. He started his professional career at Ovako Steel for 10 years and then transitioned to private equity in 1995, when he was a part of the initial team at EQT Partners. At EQT, he served in several senior positions such as Deputy CEO and Vice Chairman before leaving in 2018. He has served on the board of the Zelarion Group since 2019.

Jan Ståhlberg

Molly Chiaramonte is a former VP, Research &amp; Investments at RoyalyPharma. She previously served as a biotechnology equity research associate at Jefferies &amp; Company and completed a post-doctoral fellowship at the University of Colorado Health Sciences Center. She holds a BA in mathematics from Providence College, an MA in mathematics from the University of Colorado, and a PhD in chemistry from the University of Colorado. She has served on the board of the Zelarion Group since 2018.

Molly Chiaramonte

Shefali Agarwal is the President and CEO of Valerio Therapeutics. Previously she served as Chief Medical Officer at Epizyme, Inc., leading development strategies for cancer therapy tazemetostat. Her extensive background includes leadership roles at SQZ Biotech, Curis, and Tesaro, focusing on clinical development and regulatory submissions for cancer treatments. With previous positions at Covidien, AVEO Oncology, and Pfizer, Dr. Agarwal&#8217;s experience spans medical research and clinical operations. She holds a medical degree, a Master&#8217;s of Public Health, and a Master&#8217;s of Science in Business, reflecting her comprehensive expertise in both healthcare and business. She has served on the board of the Zelarion Group since 2020.

Shefali Agarwal

Matthew Lamb, PharmD, RPh, is a senior leader in drug development with over 25 years of experience in global development and commercialization across biotechnology, specialty, and large-cap biopharma companies, including Roche, Actavis, Celgene, and Bristol Myers Squibb. He has worked across all phases of drug development and commercialization, from pre-IND through to clinical trials (Phase I–III) and post-marketing lifecycle management.
Therapeutic areas where Matt has development expertise include transplantation, immunology, oncology, neuroscience, virology, gastroenterology, and women’s health. Matt has made significant contributions to the global registration of multiple innovative medicines, including Sotyktu™, Zeposia®, Otezla®, Delzicol®, Atelvia®, Tamiflu®, Actemra/RoActemra®, Invirase®, Pegasys®, and Copegus®.
Trained as a clinical pharmacologist, Matt also has extensive experience in global regulatory affairs and R&amp;D project and portfolio management. In recent roles, he has overseen therapeutic area drug development and program leadership. He earned both his BS and PharmD from the Philadelphia College of Pharmacy and Science and completed a post-doctoral fellowship in clinical pharmacokinetics and pharmacodynamics at the University of North Carolina at Chapel Hill.

Chief Executive Officer (Interim)

Matthew Lamb

Leslie has 20+ years of life sciences legal and compliance experience.  He has served as the General Counsel and Chief Compliance Officer for publicly-traded and privately held biopharmaceutical companies.  His legal, strategic, transactional, intellectual property and compliance experience spans the research, development, approval, launch and commercialization of innovative products.  Leslie holds a juris doctor degree from the University of Florida.

Chief Legal and Compliance Officer

Leslie Zacks

M.Sc. in Business and Economics, Finance from Stockholm University. Kasper was appointed CFO in 2018 but has been working with ITB-MED as an external finance consultant since the company was founded in 2016. Prior to joining ITB-MED Kasper has worked with corporate finance in Stockholm and has experience from IPOs, equity and debt financings as well as M&amp;A transactions.

Chief Financial Officer

Kasper Granlund

Vice President, Medical Strategy

Kellie Calderon

Filip Cvetkovski received a BSc in Molecular Biotechnology from Heidelberg University, Germany, and a PhD in Microbiology and Immunology from Columbia University in New York. Filip has over ten years of research experience in immunology and animal models of human disease.

Laboratory Director

Filip Cvetkovski

Lovisa Ringstad, PhD in Pharmacy from Uppsala University, has 15 years of experience in pharmaceutical research and development, project management and CMC from research institutes and industry. Lovisa joined ITB-MED in August 2023 and most recently come from a role as Head of CMC at Ilya Pharma AB.

 Director, Head of Chemistry Manufacturing and Controls & CMC Global Regulatory Affairs

Lovisa Ringstad

Benedetta Maria Sala holds a PhD in Molecular and Cellular Biology from the University of Milan and has over ten years of research experience in protein biology, biophysics, and structural biology. Prior to joining ITB-MED in June 2023, Benedetta Maria worked as an Assistant Professor at Karolinska Institute.

Senior Research Scientist

Benedetta Maria Sala

Michael Chrobok obtained his Ph.D. in Immunology and Cell Therapy from Karolinska Institutet in 2019, where he engineered genetically modified natural killer (NK) cells and advanced adoptive cell therapy protocols for multiple myeloma. Following his doctoral training, he expanded his scope at Karolinska Institutet’s preGMP facility, coordinating projects that established clinical-grade protocols for modifying primary human T cells. Subsequent roles as a consultant and scientist involved directing quality control assays, conducting validation assays, and integrating manufacturing processes for early-phase (I/II) clinical trials at both academic and industry sites.

 Research Scientist and Laboratory Manager

Michael Chrobok

Silvia holds a Master’s degree in Pharmaceutical Chemistry and Technology from the University of Pavia.
Before joining ITB-MED in March 2025 as CMC Project Coordinator, she worked in several pharmaceutical companies, gaining experience in analytical research laboratories and in aseptic manufacturing processes within GMP-regulated environments.

Project Coordinator, Chemistry Manufacturing and Controls

Silvia Cesti

Joke Rotticci-Mulder, PhD in Biochemistry from the Royal Institute of Technology (KTH) Stockholm Sweden, has more than 20 years experience in pharmaceutical research and development. Joke has previously worked in R&amp;D at AstraZeneca and in process development at a CDMO (Cobra Biologics). Most recently she held a role as Senior consultant to support small and medium size Biopharma companies as CMC project manager. Joke joined ITB-MED in September 2025 as Associate Director CMC.

 Associate Director, Chemistry Manufacturing and Controls

Joke Rotticci-Mulder

Karin Sewerin, PhD, initially worked with ITB-MED as a consultant in CMC regulatory affairs and Quality Assurance, and joined the company in 2024 as an advisor in CMC regulatory affairs. She has over 40 years of experience in international biopharmaceutical industry. Before joining ITB-MED she worked as a CMC and regulatory consultant in development of biotechnology derived products. She has previously worked at Kabi-Pharmacia and AstraZeneca in Sweden, holding positions as Sr scientist, Head of QC, Global Head of Regulatory CMC for Biologics, and at Genentech in USA as Head of QC for Development Products and Director of CMC Regulatory Affairs.
&nbsp;
Karin has worked with product design and selection of candidate drugs, protein characterization, development and validation of analytical methods for products in clinical trials and for commercial use. She has worked with design of control strategies including process validation, process characterization, technology transfers of clinical and marketed products and control of biotechnology derived products, and with regulatory submissions for clinical trials, registration and for life cycle management. She holds a PhD in Pharmaceutical Biochemistry at the University of Uppsala, Sweden.

Strategic Chemistry, Manufacturing and Controls Advisor

Karin Sewerin

Desiree Shrode, MA, SHRM-CP, PHR, joined ITB-MED in February 2024, bringing a wealth of experience and expertise in supporting international companies across various industries and organizations, ranging from start-ups to Top 10 S&amp;P 500 companies, within the Human Resources function. Desiree holds a Bachelor&#8217;s degree in Psychology from Oregon State University, a Master&#8217;s degree in Education, Leadership, and Policy from Portland State University, and a Master&#8217;s degree in International Education from the School for International Training. She is an active member of the Society for Human Resource Management and holds both SHRM-CP and PHR certifications, underscoring her comprehensive knowledge and commitment to the HR field.
Throughout her career, Desiree has demonstrated expertise in building HR departments from the ground up. Her skills encompass HR strategy and operations, performance management, recruitment, employee relations, compensation and benefits strategy, payroll, and employment laws and regulations.
In her current role at ITB-MED, Desiree drives the HR strategy to ensure alignment with organizational goals. She is responsible for strategic HR planning and policy development, while fostering a positive and collaborative work environment. Desiree is passionate about her work and is dedicated to ITB-MED’s meaningful mission of improving patient outcomes.

Associate Director, Human Resources

Desiree Shrode

Susanne joined ITB-MED in October 2018 and tends to HR &amp; Workplace matters within the organization. She is also responsible for handling the day-to-day operations in the Stockholm office. She has extensive experience from various administrative roles in different industries.

 Senior Manager, HR

Susanne Svärd

Elina joined the ITB-MED team in October 2023. 
As Workplace Coordinator, she adeptly manages various aspects of workplace matters, including office operations, employee support and serving as the primary point of contact for vendors and partners. Elina&#8217;s role extends across all departments, providing assistance to employees and teams. 
<div>
Elina has several years of experience in customer service and various administrative roles. Her background encompasses working for both startup companies and larger multinational corporations.
</div>

 Senior Coordinator, SHE and Workplace

Elina Tusach Chacana

Anna-Karin joined ITB-MED in 2019 as a Financial Controller and has over 20 years of experience in finance, leadership and administration in various industries, mainly in smaller as well as major international listed group companies. She has a degree in management &amp; finance and in addition to this, she is also a certified coach.

Associate Director, Finance and Treasury

Anna-Karin Lindblad

Ulrica joined ITB-MED in 2024 as Associate Director, Accounting, bringing over a decade of experience in finance, accounting, and leadership across various industries. She has held key roles in financial management, business controlling, and strategic reporting at multiple companies. Ulrica holds a degree in Economics (Accounting) from Stockholms universitet and has further enhanced her leadership skills through leadership programs.

Associate Director, Accounting

Ulrica Madison da Correggio

Terese joined ITB-MED in 2022 as an Accountant, working mostly with Accounts Payables and Legal Administration. She has extensive experience from finance and administration from various industries, mainly in smaller and midsized companies in both the private as well as the public sector.

Senior Manager, Accounting

Terese Bylund

Nathalie Grip holds a Bachelor’s degree from Lund University and gained three years of experience as a Paralegal before joining the ITB-MED team in September 2024. With a strong background in administrative roles across both small enterprises and global corporations, she has developed extensive proficiency in legal and administrative operations. In her current role, Nathalie provides comprehensive support to the Chief Legal and Compliance Officer, assisting with all matters related to legal and compliance.

Paralegal

Nathalie Grip

Mikael has an educational background in Biotechnology Engineering from KTH Royal Institute of Technology. Prior to joining ITB-MED, Mikael worked at a CRO, most recently as an IT Manager overseeing the company’s IT expansion from a start-up to a scale-up.

Associate Director, Head of Information Technology

Mikael Holmqvist

Our team has a long experience from pharmaceutical research and development, business development, entrepreneurship, transplantation surgery and immunology. We are located across two continents covering the global operations.

Join us now

We’re developing an innovative therapy that would potentially empower transplant patients to reclaim their freedom and quality of life – all without the need for immunosuppressive medications.

Meet the team

Help us make a real difference